Stimuli-Responsive Nanoadjuvant Rejuvenates Robust Immune Responses to Sensitize Cancer Immunotherapy
- 28 October 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 17 (21) , 21455-21469
Abstract
Despite their immense therapeutic potential, cancer immunotherapies such as immune checkpoint blockers (ICBs) benefit only a small subset of patients. Toll-like receptor agonists reverse the immunosuppressive tumor microenvironment (TME) to enhance antitumor immunity, but their systemic administration induces side effects. This work describes a TME-responsive nanotherapeutic platform for the site-specific release of drug candidates in tumors with a significant antitumor efficacy. Imidazoquinoline (IMQ)-derived liposomal nanovesicles (LN-IMQ) triggered the antitumor ability of macrophages, mobilized T-cell immunity, and promoted the secretion of antitumor cytokines, explaining the synergistic effect of LN-IMQ with ICBs. LN-IMQ monotherapy observed complete tumor regression in 6/8 of 4T1-bearing mouse, and cured mice resisted secondary tumor challenge. Besides, LN-IMQ decreased the occurrence of lung metastases, being effective against advanced metastases. On the other hand, neoantigen-based cancer vaccine has very low immune responses. Here, we also verified that LN-IMQ can serve as an ideal tumor antigen delivery vector. Cancer cells in vitro treated with chemotherapeutic drugs included multiple neoantigens and high levels of damage-associated molecular patterns, which were then successfully encapsulated in LN-IMQ to obtain a "personalized nanovaccine" with artificially amplified antigenicity and adjuvant properties. This study developed an attractive potential personalized nanovaccine for chemotherapeutic-drug-induced tumor neoantigens and immunotherapy.Keywords
Funding Information
- University of Science and Technology of China (KJ2060190030, KY2060000124)
- National Medical Research Council (CG21APR1005, OFIRG23jan-0005)
- Ministry of Education - Singapore (MOE-000387-00)
- National University of Singapore (NUHSRO/2020/133/Startup/08, NUHSRO/2021/034/TRP/09/Nanomedicine, NUHSRO/2023/008/NUSMed/TCE/LOA)
- Fundamental Research Funds for the Central Universities (WK2060190101, WK9110000103, WK9110000144, WK9110000151, WY2060190092)
- National Natural Science Foundation of China (31971299, 82102953, GG2060190386, GG2065010001)
- National Research Foundation (NRF-000352-00)
This publication has 46 references indexed in Scilit:
- Co-delivery of immunomodulators in biodegradable nanoparticles improves therapeutic efficacy of cancer vaccinesBiomaterials, 2019
- LRP6 Ectodomain Prevents SDF-1/CXCR4-Induced Breast Cancer Metastasis to LungClinical Cancer Research, 2019
- Long-term implant fibrosis prevention in rodents and non-human primates using crystallized drug formulationsNature Materials, 2019
- A toll-like receptor agonist mimicking microbial signal to generate tumor-suppressive macrophagesNature Communications, 2019
- Delivery technologies for cancer immunotherapyNature Reviews Drug Discovery, 2019
- TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapyNature Biomedical Engineering, 2018
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeNew England Journal of Medicine, 2018
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- Incorporation and Controlled Release of Silyl Ether Prodrugs from PRINT NanoparticlesJournal of the American Chemical Society, 2012
- Universal sample preparation method for proteome analysisNature Methods, 2009